Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The aim is to evaluate the effect of ketamine with or without magnesium in 22 patients with neuropathic pain.

Why It Was Studied

Ketamine is widely used in French pain clinics, but without consensus or recommendations.

Registered on April 9, 2015; version 1.4.

Who Took Part

The study group was 22 patients.

Intravenous ketamine/placebo, ketamine/magnesium sulfate, or placebo/placebo will be administered consecutively to each patient, in random order, once at 5-week intervals.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.

A randomized, double-blind, crossover, placebo-controlled study will be performed in Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

What Was Measured

PubMed files the paper under topics including Administration, Intravenous, Analgesics, Clinical Protocols, Drug Combinations, France, Hospitals, University and Intention to Treat Analysis.

The authors tagged it with the keywords Ketamine, Magnesium sulfate, N-methyl-D-aspartate receptor, Neuropathic pain and Placebo.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 1 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Trials), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.